Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells

Faith B. Davis, Heng Yuan Tang, Ai Shih, Travis Keating, Lawrence Lansing, Aleck Hercbergs, Robert A. Fenstermaker, Ahmed Mousa, Shaker A. Mousa, Paul J. Davis, Hung Y. Lin

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Recent evidence suggests that the thyroid hormone L-thyroxine (T 4) stimulates growth of cancer cells via a plasma membrane receptor on integrin αVβ3. The contribution of this recently described receptor for thyroid hormone and receptor-based stimulation of cellular mitogen-activated protein kinase [MAPK; extracellular signal-regulated kinase 1/2 (ERK1/2)] activity, to enhancement of cell proliferation by thyroid hormone was quantitated functionally and by immunologic means in three glioma cell lines exposed to T4. At concentrations of 1 to 100 nmol/L, T4 caused proliferation of C6, F98, and GL261 cells, measured by accumulation of proliferating cell nuclear antigen (PCNA) and radiolabeled thymidine incorporation. This effect was inhibited by the T 4 analogue, tetraiodothyroacetic acid, and by an α Vβ3 RGD recognition site peptide, both of which block T4 binding to integrin αVβ3 but are not agonists. Activation of MAPK by T4 was similarly inhibited by tetraiodothyroacetic acid and the RGD peptide. The thyroid hormone 3,5,3′-triiodo-L-thyronine (T3) and T4 were equipotent stimulators of PCNA accumulation in C6, F98, and GL261 cells, but physiologic concentrations of T3 are 50-fold lower than those of T4. In conclusion, our studies suggest that glioblastoma cells are thyroid hormone dependent and provide a molecular basis for recent clinical observations that induction of mild hypothyroidism may improve duration of survival in glioblastoma patients. The present experiments infer a novel cell membrane receptor-mediated basis for the growth-promoting activity of thyroid hormone in such tumors and suggest new therapeutic approaches to the treatment of patients with glioblastoma.

Original languageEnglish
Pages (from-to)7270-7275
Number of pages6
JournalCancer Research
Volume66
Issue number14
DOIs
Publication statusPublished - Jul 15 2006
Externally publishedYes

Fingerprint

Cell Surface Receptors
Thyroid Hormones
Glioma
Intercellular Signaling Peptides and Proteins
Glioblastoma
Proliferating Cell Nuclear Antigen
Integrins
MAP Kinase Kinase 2
Cell Membrane
Thyronines
Thyroid Hormone Receptors
Mitogen-Activated Protein Kinase 3
Hypothyroidism
Mitogen-Activated Protein Kinases
Thyroxine
Thymidine
Neoplasms
Cell Proliferation
Cell Line
Peptides

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. / Davis, Faith B.; Tang, Heng Yuan; Shih, Ai; Keating, Travis; Lansing, Lawrence; Hercbergs, Aleck; Fenstermaker, Robert A.; Mousa, Ahmed; Mousa, Shaker A.; Davis, Paul J.; Lin, Hung Y.

In: Cancer Research, Vol. 66, No. 14, 15.07.2006, p. 7270-7275.

Research output: Contribution to journalArticle

Davis, FB, Tang, HY, Shih, A, Keating, T, Lansing, L, Hercbergs, A, Fenstermaker, RA, Mousa, A, Mousa, SA, Davis, PJ & Lin, HY 2006, 'Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells', Cancer Research, vol. 66, no. 14, pp. 7270-7275. https://doi.org/10.1158/0008-5472.CAN-05-4365
Davis FB, Tang HY, Shih A, Keating T, Lansing L, Hercbergs A et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Research. 2006 Jul 15;66(14):7270-7275. https://doi.org/10.1158/0008-5472.CAN-05-4365
Davis, Faith B. ; Tang, Heng Yuan ; Shih, Ai ; Keating, Travis ; Lansing, Lawrence ; Hercbergs, Aleck ; Fenstermaker, Robert A. ; Mousa, Ahmed ; Mousa, Shaker A. ; Davis, Paul J. ; Lin, Hung Y. / Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. In: Cancer Research. 2006 ; Vol. 66, No. 14. pp. 7270-7275.
@article{574a5db4dc134bedac5f607f329b0984,
title = "Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells",
abstract = "Recent evidence suggests that the thyroid hormone L-thyroxine (T 4) stimulates growth of cancer cells via a plasma membrane receptor on integrin αVβ3. The contribution of this recently described receptor for thyroid hormone and receptor-based stimulation of cellular mitogen-activated protein kinase [MAPK; extracellular signal-regulated kinase 1/2 (ERK1/2)] activity, to enhancement of cell proliferation by thyroid hormone was quantitated functionally and by immunologic means in three glioma cell lines exposed to T4. At concentrations of 1 to 100 nmol/L, T4 caused proliferation of C6, F98, and GL261 cells, measured by accumulation of proliferating cell nuclear antigen (PCNA) and radiolabeled thymidine incorporation. This effect was inhibited by the T 4 analogue, tetraiodothyroacetic acid, and by an α Vβ3 RGD recognition site peptide, both of which block T4 binding to integrin αVβ3 but are not agonists. Activation of MAPK by T4 was similarly inhibited by tetraiodothyroacetic acid and the RGD peptide. The thyroid hormone 3,5,3′-triiodo-L-thyronine (T3) and T4 were equipotent stimulators of PCNA accumulation in C6, F98, and GL261 cells, but physiologic concentrations of T3 are 50-fold lower than those of T4. In conclusion, our studies suggest that glioblastoma cells are thyroid hormone dependent and provide a molecular basis for recent clinical observations that induction of mild hypothyroidism may improve duration of survival in glioblastoma patients. The present experiments infer a novel cell membrane receptor-mediated basis for the growth-promoting activity of thyroid hormone in such tumors and suggest new therapeutic approaches to the treatment of patients with glioblastoma.",
author = "Davis, {Faith B.} and Tang, {Heng Yuan} and Ai Shih and Travis Keating and Lawrence Lansing and Aleck Hercbergs and Fenstermaker, {Robert A.} and Ahmed Mousa and Mousa, {Shaker A.} and Davis, {Paul J.} and Lin, {Hung Y.}",
year = "2006",
month = "7",
day = "15",
doi = "10.1158/0008-5472.CAN-05-4365",
language = "English",
volume = "66",
pages = "7270--7275",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells

AU - Davis, Faith B.

AU - Tang, Heng Yuan

AU - Shih, Ai

AU - Keating, Travis

AU - Lansing, Lawrence

AU - Hercbergs, Aleck

AU - Fenstermaker, Robert A.

AU - Mousa, Ahmed

AU - Mousa, Shaker A.

AU - Davis, Paul J.

AU - Lin, Hung Y.

PY - 2006/7/15

Y1 - 2006/7/15

N2 - Recent evidence suggests that the thyroid hormone L-thyroxine (T 4) stimulates growth of cancer cells via a plasma membrane receptor on integrin αVβ3. The contribution of this recently described receptor for thyroid hormone and receptor-based stimulation of cellular mitogen-activated protein kinase [MAPK; extracellular signal-regulated kinase 1/2 (ERK1/2)] activity, to enhancement of cell proliferation by thyroid hormone was quantitated functionally and by immunologic means in three glioma cell lines exposed to T4. At concentrations of 1 to 100 nmol/L, T4 caused proliferation of C6, F98, and GL261 cells, measured by accumulation of proliferating cell nuclear antigen (PCNA) and radiolabeled thymidine incorporation. This effect was inhibited by the T 4 analogue, tetraiodothyroacetic acid, and by an α Vβ3 RGD recognition site peptide, both of which block T4 binding to integrin αVβ3 but are not agonists. Activation of MAPK by T4 was similarly inhibited by tetraiodothyroacetic acid and the RGD peptide. The thyroid hormone 3,5,3′-triiodo-L-thyronine (T3) and T4 were equipotent stimulators of PCNA accumulation in C6, F98, and GL261 cells, but physiologic concentrations of T3 are 50-fold lower than those of T4. In conclusion, our studies suggest that glioblastoma cells are thyroid hormone dependent and provide a molecular basis for recent clinical observations that induction of mild hypothyroidism may improve duration of survival in glioblastoma patients. The present experiments infer a novel cell membrane receptor-mediated basis for the growth-promoting activity of thyroid hormone in such tumors and suggest new therapeutic approaches to the treatment of patients with glioblastoma.

AB - Recent evidence suggests that the thyroid hormone L-thyroxine (T 4) stimulates growth of cancer cells via a plasma membrane receptor on integrin αVβ3. The contribution of this recently described receptor for thyroid hormone and receptor-based stimulation of cellular mitogen-activated protein kinase [MAPK; extracellular signal-regulated kinase 1/2 (ERK1/2)] activity, to enhancement of cell proliferation by thyroid hormone was quantitated functionally and by immunologic means in three glioma cell lines exposed to T4. At concentrations of 1 to 100 nmol/L, T4 caused proliferation of C6, F98, and GL261 cells, measured by accumulation of proliferating cell nuclear antigen (PCNA) and radiolabeled thymidine incorporation. This effect was inhibited by the T 4 analogue, tetraiodothyroacetic acid, and by an α Vβ3 RGD recognition site peptide, both of which block T4 binding to integrin αVβ3 but are not agonists. Activation of MAPK by T4 was similarly inhibited by tetraiodothyroacetic acid and the RGD peptide. The thyroid hormone 3,5,3′-triiodo-L-thyronine (T3) and T4 were equipotent stimulators of PCNA accumulation in C6, F98, and GL261 cells, but physiologic concentrations of T3 are 50-fold lower than those of T4. In conclusion, our studies suggest that glioblastoma cells are thyroid hormone dependent and provide a molecular basis for recent clinical observations that induction of mild hypothyroidism may improve duration of survival in glioblastoma patients. The present experiments infer a novel cell membrane receptor-mediated basis for the growth-promoting activity of thyroid hormone in such tumors and suggest new therapeutic approaches to the treatment of patients with glioblastoma.

UR - http://www.scopus.com/inward/record.url?scp=33746897636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746897636&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-4365

DO - 10.1158/0008-5472.CAN-05-4365

M3 - Article

VL - 66

SP - 7270

EP - 7275

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 14

ER -